PharmiWeb.com - Global Pharma News & Resources
01-Feb-2022

Waters Corporation (NYSE: WAT) Reports Fourth Quarter and Full-Year 2021 Financial Results

  • Fourth quarter sales of $836 million grew 8% in constant currency, 6% as reported
  • Quarter led by double-digit instrument sales growth, with momentum increasing on a two year stacked basis into year-end
  • Transformation on track with strong growth in 2021 as instrument sales and recurring revenues grew across all regions, delivering 16% growth in constant currency, 18% as reported
  • Full-year GAAP EPS of $11.17; non-GAAP EPS of $11.20, a 24% increase from prior year

MILFORD, Mass.--(BUSINESS WIRE)--Waters Corporation (NYSE: WAT) today announced fourth quarter 2021 sales of $836 million, an increase of 6% as reported and 8% in constant currency, compared to sales of $787 million for the fourth quarter of 2020.


On a GAAP basis, diluted earnings per share (EPS) for the fourth quarter of 2021 increased to $3.52, compared to $3.49 for the fourth quarter of 2020. On a non-GAAP basis, EPS increased to $3.67, compared to $3.65 for the fourth quarter of 2020. A description and reconciliation of GAAP to non-GAAP results appear in the tables below and can be found on the Company’s website www.waters.com in the Investor Relations section.

On a GAAP basis, net cash provided by operating activities was $218 million for the fourth quarter of 2021, compared to $267 million for the fourth quarter of 2020. On a non-GAAP basis, adjusted free cash flow for the fourth quarter of 2021 was $187 million versus $240 million for the fourth quarter of 2020.

For fiscal year 2021, the Company’s sales were $2,786 million, an increase of 18% as reported and 16% in constant currency, compared to sales of $2,365 million for fiscal year 2020.

On a GAAP basis, EPS for fiscal year 2021 increased to $11.17, compared to $8.36 for fiscal year 2020. On a non-GAAP basis, EPS increased to $11.20, compared to $9.05 for fiscal year 2020.

On a GAAP basis, net cash provided by operating activities was $747 million for fiscal year 2021, compared to $791 million for fiscal year 2020. On a non-GAAP basis, adjusted free cash flow for fiscal year 2021 was $675 million versus $726 million for fiscal year 2020.

“I am extremely grateful for our colleagues around the world who continue to overcome the challenges of the pandemic while delivering exceptional support to our customers,” said Dr. Udit Batra, President and Chief Executive Officer of Waters Corporation. “We saw strong momentum in our two-year stacked revenue growth throughout 2021, demonstrating that our transformation is truly embedded into how we operate. In the fourth quarter, we capitalized on broad-based growth across our end markets and geographies, with particular strength in biopharma, industrial and China. Despite a tougher comparison and six fewer days in the quarter, consumables and instruments contributed solid gains.”

Dr. Batra continued, “As we close the books on 2021, I am very pleased with the revitalization of our core systems portfolio and the growing contributions of new products such as ACQUITY Premier, Arc HPLC, Multi-Reflecting ToF mass spec and our TA Instruments Discovery product line, all setting us up for years to come.”

Financial Highlights

Unless otherwise noted, sales growth and decline percentages are presented on an as-reported basis and are the same as the sales growth and decline percentages presented on a constant currency basis as compared with the same period in the prior year, each of which is detailed in the reconciliation of sales growth rates to constant currency growth rates in the tables below.

During the fourth quarter of 2021, sales into the pharmaceutical market increased 7% as reported and 8% in constant currency, sales into the industrial market increased 6% as reported and 7% in constant currency and sales into the academic and government markets increased 4% as reported and 5% in constant currency.

Recurring revenues, which represent the combination of service and precision chemistries, increased 2% as reported and 3% in constant currency, with six fewer days in the fourth quarter of 2021, while instrument system sales increased 10% as reported and 12% in constant currency.

Geographically, sales in Asia during the quarter increased 9%, sales in the Americas increased 8% (with U.S. sales growing 8%), and sales in Europe increased 1% as reported and 5% in constant currency.

For fiscal year 2021, sales into the pharmaceutical market increased 20% as reported and 19% in constant currency, sales into the industrial market increased 17% as reported and 15% in constant currency and sales into the academic and government markets increased 7% as reported and 5% in constant currency.

Recurring revenues increased 13% as reported and 11% in constant currency, while instrument system sales increased 23%.

Geographically, sales in Asia increased 20% as reported and 19% in constant currency, sales in the Americas increased 16% (with U.S. sales growing 14%) and sales in Europe increased 17% as reported and 14% in constant currency.

First Quarter and Full-Year 2022 Financial Outlook

The Company expects full-year 2022 constant currency sales growth in the range of 5% to 7%. Currency translation is expected to decrease full-year sales growth by approximately one percentage point. The Company expects full-year 2022 non-GAAP EPS in the range of $11.75 to $12.00. Please refer to the tables below for a reconciliation of the projected GAAP to non-GAAP financial outlook for the full-year.

The Company expects first quarter 2022 constant currency sales growth in the range of 6% to 8%. Currency translation is expected to decrease first quarter sales growth by approximately three percentage points. The Company expects first quarter 2022 non-GAAP EPS in the range of $2.25 to $2.35. Please refer to the tables below for a reconciliation of the projected GAAP to non-GAAP financial outlook for the fourth quarter.

Conference Call

Waters Corporation will webcast its fourth quarter and full-year 2021 financial results conference call today, February 1, 2022 at 8:00 a.m. Eastern Time. To listen to the call and see the accompanying slide presentation, please visit www.waters.com, select “Investors” under the “About Waters” section, navigate to “Events & Presentations,” and click on the “Webcast.” A replay will be available through at least February 15, 2022 at midnight Eastern Time on the same website by webcast and also by phone at (888) 566-0450.

About Waters Corporation

Waters Corporation (NYSE: WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry and thermal analysis innovations serving the life, materials and food sciences for more than 60 years. With more than 7,400 employees worldwide, Waters operates directly in 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries. For more information, visit www.waters.com.

Non-GAAP Financial Measures

This press release contains financial measures, such as constant currency growth rate, adjusted operating income, adjusted net income, adjusted earnings per diluted share and adjusted free cash flow, among others, which are considered “non-GAAP” financial measures under applicable U.S. Securities and Exchange Commission rules and regulations. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with U.S. generally accepted accounting principles (GAAP). The Company’s definitions of these non-GAAP measures may differ from similarly titled measures used by others. The non-GAAP financial measures used in this press release adjust for specified items that can be highly variable or difficult to predict. The Company generally uses these non-GAAP financial measures to facilitate management’s financial and operational decision-making, including evaluation of the Company’s historical operating results, comparison to competitors’ operating results and determination of management incentive compensation. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting the Company’s business. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company’s reported results of operations, management strongly encourages investors to review the Company’s consolidated financial statements and publicly filed reports in their entirety. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the tables accompanying this release.

Cautionary Statement

This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “feels”, “believes”, “anticipates”, “plans”, “expects”, “intends”, “suggests”, “appears”, “estimates”, “projects” and similar expressions, whether in the negative or affirmative, are intended to identify forward-looking statements. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements within this release for a variety of reasons, including and without limitation, risks related to the effects of the ongoing COVID-19 pandemic on our business, financial condition, results of operations and prospects, including: portions of our global workforce being unable to work fully and/or effectively due to working remotely, illness, quarantines, government actions, facility closures or other reasons related to the pandemic, increased risks of cyber-attacks resulting from our temporary remote working model, disruptions in our manufacturing capabilities or to our supply chain and distribution network, volatility and uncertainty in global capital markets limiting our ability to access capital, customers being unable to make timely payments for purchases and volatility in demand for our products; foreign exchange rate fluctuations potentially affecting translation of the Company’s future non-U.S. operating results; the impact on demand for the Company’s products, including delays or disruptions to our distribution network, among the Company’s various market sectors or geographies from economic, sovereign and political uncertainties, particularly regarding the effect of new or proposed tariff or trade regulations or changes in the interpretation or enforcement of existing regulations; the effect on the Company’s financial results from the United Kingdom exiting the European Union; fluctuations in expenditures by the Company’s customers, in particular large pharmaceutical companies; introduction of competing products by other companies and loss of market share; pressures on prices from competitors and/or customers; regulatory, economic and competitive obstacles to new product introductions; other changes in demand for the Company’s products from the effect of mergers and acquisitions by the Company’s customers; increased regulatory burdens as the Company’s business evolves, especially with respect to the U.S. Food and Drug Administration and U.S. Environmental Protection Agency, among others; shifts in taxable income in jurisdictions with different effective tax rates; the outcome of tax examinations or changes in respective country legislation affecting the Company’s effective tax rate; the effect of the adoption of new accounting standards; the ability to access capital, maintain liquidity and service the Company’s debt in volatile market conditions, including any potential impact on the Company’s operations stemming from sustained inflation, particularly in the U.S., as a large portion of the Company’s cash is held and operating cash flows are generated outside the U.S.; environmental and logistical obstacles affecting the distribution of products and risks associated with lawsuits and other legal actions, particularly involving claims for infringement of patents and other intellectual property rights. Such factors and others are discussed more fully in the sections entitled “Forward-Looking Statements” and “Risk Factors” of the Company’s annual report on Form 10-K for the year ended December 31, 2020, as well as in the sections entitled “Special Note Regarding Forward-Looking Statements” and “Risk Factors” of the Company’s quarterly reports on Form 10-Q for the quarterly periods ended April 3, 2021, July 3, 2021, and October 2, 2021, each as filed with the Securities and Exchange Commission (“SEC”), which discussions are incorporated by reference in this release, as updated by the Company’s future filings with the SEC. The forward-looking statements included in this release represent the Company’s estimates or views as of the date of this release and should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this release. Except as required by law, the Company does not assume any obligation to update any forward-looking statements.

Waters Corporation and Subsidiaries
Consolidated Statements of Operations
(In thousands, except per share data)
(Unaudited)
 
 
Three Months Ended Twelve Months Ended
December 31, 2021 December 31, 2020 December 31, 2021 December 31, 2020
 
Net sales

$

836,449

 

$

786,658

 

$

2,785,874

 

$

2,365,365

 

 
Costs and operating expenses:
Cost of sales

 

351,004

 

 

320,569

 

 

1,156,533

 

 

1,006,689

 

Selling and administrative expenses

 

173,014

 

 

153,084

 

 

626,968

 

 

553,698

 

Research and development expenses

 

43,331

 

 

39,662

 

 

168,358

 

 

140,777

 

Purchased intangibles amortization

 

1,735

 

 

2,687

 

 

7,143

 

 

10,587

 

Asset impairment(a)

 

-

 

 

6,945

 

 

-

 

 

6,945

 

Litigation provision

 

5,165

 

 

-

 

 

5,165

 

 

1,180

 

 
Operating income

 

262,200

 

 

263,711

 

 

821,707

 

 

645,489

 

 
Other (expense) income, net (b)

 

(870

)

 

374

 

 

17,203

 

 

(1,775

)

Interest expense, net

 

(9,010

)

 

(6,834

)

 

(32,717

)

 

(32,800

)

 
Income from operations before income taxes

 

252,320

 

 

257,251

 

 

806,193

 

 

610,914

 

 
Provision for income taxes

 

36,081

 

 

38,940

 

 

113,350

 

 

89,343

 

 
Net income

$

216,239

 

$

218,311

 

$

692,843

 

$

521,571

 

 
 
Net income per basic common share

$

3.55

 

$

3.51

 

$

11.25

 

$

8.40

 

 
Weighted-average number of basic common shares

 

60,984

 

 

62,170

 

 

61,575

 

 

62,094

 

 
 
Net income per diluted common share

$

3.52

 

$

3.49

 

$

11.17

 

$

8.36

 

 
Weighted-average number of diluted common shares and equivalents

 

61,423

 

 

62,501

 

 

62,028

 

 

62,414

 

(a) The asset impairment incurred during the three and twelve months ended December 31, 2020 included a non-cash impairment charge of $10 million related to certain intangible assets previously acquired. In conjunction with the intangible asset impairment charge, the Company also reduced its liability for contingent consideration of $3 million during the three and twelve months ended December 31, 2020. The net impact of $7 million is reported as an asset impairment in the consolidated statements of operations.
 
(b) During the twelve months ended December 31, 2021, the Company executed a settlement agreement to resolve patent infringement litigation with Bruker Corporation and Bruker Daltronik GmbH regarding their timsTOF product line. In connection with the settlement, the Company is entitled to receive $10 million in guaranteed payments, including minimum royalty payments, which was recognized within Other (expense) income, net in our consolidated statement of operations. During the twelve months ended December 31, 2021, the Company recorded an unrealized gain of $10 million due to an observable change in the fair value of an existing investment the Company does not have the ability to exercise significant influence over.
Waters Corporation and Subsidiaries
Reconciliation of GAAP to Adjusted Non-GAAP
Net Sales by Operating Segments, Products & Services, Geography and Markets
Three Months Ended December 31, 2021 and December 31, 2020
(In thousands)
Current
Period Constant
Three Months Ended Percent Currency Currency
December 31, 2021 December 31, 2020 Change Impact Growth Rate (a)
 
NET SALES - OPERATING SEGMENTS
 
Waters

$

742,070

$

703,738

5

%

$

(8,433

)

7

%

TA

 

94,379

 

82,920

14

%

 

(1,591

)

16

%

 

 

 

 

Total

$

836,449

$

786,658

6

%

$

(10,024

)

8

%

 

 

 

 

 

 

 

 

NET SALES - PRODUCTS & SERVICES

 

 

 

 

 

 

 

 

Instruments

$

441,229

$

400,436

10

%

$

(7,965

)

12

%

 

 

 

 

Service

 

256,489

 

254,667

1

%

 

(2,932

)

2

%

Chemistry

 

138,731

 

131,555

5

%

 

873

 

5

%

Total Recurring

 

395,220

 

386,222

2

%

 

(2,059

)

3

%

 

 

 

 

Total

$

836,449

$

786,658

6

%

$

(10,024

)

8

%

 

 

 

 

 

 

 

 

NET SALES - GEOGRAPHY

 

 

 

 

 

 

 

 

Asia

$

321,674

$

295,706

9

%

$

(988

)

9

%

Americas

 

271,968

 

251,437

8

%

 

384

 

8

%

Europe

 

242,807

 

239,515

1

%

 

(9,420

)

5

%

 

 

 

 

Total

$

836,449

$

786,658

6

%

$

(10,024

)

8

%

 

 

 

 

 

 

 

 

NET SALES - MARKETS

 

 

 

 

 

 

 

 

Pharmaceutical

$

491,870

$

460,384

7

%

$

(7,068

)

8

%

Industrial

 

247,320

 

233,180

6

%

 

(2,440

)

7

%

Academic & Government

 

97,259

 

93,094

4

%

 

(516

)

5

%

 

 

 

 

Total

$

836,449

$

786,658

6

%

$

(10,024

)

8

%

 

 

 

 

 

 

 

 

NET SALES - EXCLUDING CHINA

 

 

 

 

 

 

 

 

Total Net Sales

$

836,449

$

786,658

6

%

$

(10,024

)

8

%

China Net Sales

 

175,098

 

151,639

15

%

 

3,460

 

13

%

 

 

 

 

Total Net Sales Excluding China

$

661,351

$

635,019

4

%

$

(13,484

)

6

%

____________________
(a) The Company believes that referring to comparable constant currency growth rates is a useful way to evaluate the underlying performance of Waters Corporation's net sales. Constant currency growth rate, a non-GAAP financial measure, measures the change in net sales between current and prior year periods, ignoring the impact of foreign currency exchange rates during the current period. See description of non-GAAP financial measures contained in this release.
Waters Corporation and Subsidiaries
Reconciliation of GAAP to Adjusted Non-GAAP
Net Sales by Operating Segments, Products & Services, Geography and Markets
Twelve Months Ended December 31, 2021 and December 31, 2020
(In thousands)
Current
Period Constant
Twelve Months Ended Percent Currency Currency
December 31, 2021 December 31, 2020 Change Impact Growth Rate (a)
 
NET SALES - OPERATING SEGMENTS
 
Waters

$

2,473,083

$

2,117,124

17

%

$

28,714

15

%

TA

 

312,791

 

248,241

26

%

 

3,622

25

%

 

 

 

 

 

Total

$

2,785,874

$

2,365,365

18

%

$

32,336

16

%

 

 

 

 

 

 

 

 

 

 

NET SALES - PRODUCTS & SERVICES

 

 

 

 

 

 

 

 

 

 

Instruments

$

1,314,861

$

1,065,253

23

%

$

5,698

23

%

 

 

 

 

 

Service

 

963,804

 

868,032

11

%

 

15,696

9

%

Chemistry

 

507,209

 

432,080

17

%

 

10,942

15

%

Total Recurring

 

1,471,013

 

1,300,112

13

%

 

26,638

11

%

 

 

 

 

 

Total

$

2,785,874

$

2,365,365

18

%

$

32,336

16

%

 

 

 

 

 

 

 

 

 

 

NET SALES - GEOGRAPHY

 

 

 

 

 

 

 

 

 

 

Asia

$

1,075,765

$

899,177

20

%

$

7,093

19

%

Americas

 

925,220

 

797,842

16

%

 

2,455

16

%

Europe

 

784,889

 

668,346

17

%

 

22,788

14

%

 

 

 

 

 

Total

$

2,785,874

$

2,365,365

18

%

$

32,336

16

%

 

 

 

 

 

 

 

 

 

 

NET SALES - MARKETS

 

 

 

 

 

 

 

 

 

 

Pharmaceutical

$

1,667,061

$

1,386,966

20

%

$

15,542

19

%

Industrial

 

829,204

 

707,772

17

%

 

12,430

15

%

Academic & Government

 

289,609

 

270,627

7

%

 

4,364

5

%

 

 

 

 

 

Total

$

2,785,874

$

2,365,365

18

%

$

32,336

16

%

 

 

 

 

 

 

 

 

 

 

NET SALES - EXCLUDING CHINA

 

 

 

 

 

 

 

 

 

 

Total Net Sales

$

2,785,874

$

2,365,365

18

%

$

32,336

16

%

China Net Sales

 

521,128

 

404,352

29

%

 

15,159

25

%

 

 

 

 

 

Total Net Sales Excluding China

$

2,264,746

$

1,961,013

15

%

$

17,177

15

%

____________________
(a) The Company believes that referring to comparable constant currency growth rates is a useful way to evaluate the underlying performance of Waters Corporation's net sales. Constant currency growth rate, a non-GAAP financial measure, measures the change in net sales between current and prior year periods, ignoring the impact of foreign currency exchange rates during the current period. See description of non-GAAP financial measures contained in this release.
Waters Corporation and Subsidiaries
Reconciliation of GAAP to Adjusted Non-GAAP Financials
Three and Twelve Months Ended December 31, 2021 and December 31, 2020
(In thousands, except per share data)
 

 

 

 

 

 

 

 

 

Income from

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operations

 

 

 

 

 

 

Selling &

 

 

 

Operating

 

Other

 

before

 

Provision for

 

 

 

Diluted

Administrative

 

Operating

 

Income

 

Income

 

Income

 

Income

 

Net

 

Earnings

Expenses(a)

 

Income

 

Percentage

 

(Expense)

 

Taxes

 

Taxes

 

Income

 

per Share

Three Months Ended December 31, 2021
GAAP

$

179,914

 

$

262,200

31.3

%

$

(870

)

$

252,320

 

$

36,081

 

$

216,239

 

$

3.52

 

Adjustments:

 

 

 

 

 

 

 

 

Purchased intangibles amortization (b)

 

(1,735

)

 

1,735

0.2

%

 

-

 

 

1,735

 

 

392

 

 

1,343

 

 

0.02

 

Restructuring costs and certain other items (c)

 

(3,669

)

 

3,669

0.4

%

 

-

 

 

3,669

 

 

783

 

 

2,886

 

 

0.05

 

Pension expenses (d)

 

-

 

 

-

-

 

 

109

 

 

109

 

 

33

 

 

76

 

 

-

 

Litigation provision (e)

 

(5,165

)

 

5,165

0.6

%

 

-

 

 

5,165

 

 

1,240

 

 

3,925

 

 

0.06

 

Certain income tax items (f)

 

-

 

 

-

-

 

 

-

 

 

-

 

 

(653

)

 

653

 

 

0.01

 

Adjusted Non-GAAP

$

169,345

 

$

272,769

32.6

%

$

(761

)

$

262,998

 

$

37,876

 

$

225,122

 

$

3.67

 

 

 

 

 

 

 

 

 

Three Months Ended December 31, 2020

 

 

 

 

 

 

 

 

GAAP

$

162,716

 

$

263,711

33.5

%

$

374

 

$

257,251

 

$

38,940

 

$

218,311

 

$

3.49

 

Adjustments:

 

 

 

 

 

 

 

 

Purchased intangibles amortization (b)

 

(2,687

)

 

2,687

0.3

%

 

-

 

 

2,687

 

 

541

 

 

2,146

 

 

0.03

 

Asset Impairment (g)

 

(6,945

)

 

6,945

0.9

%

 

-

 

 

6,945

 

 

1,180

 

 

5,765

 

 

0.09

 

Restructuring costs and certain other items (c)

 

(2,142

)

 

2,142

0.3

%

 

(1,623

)

 

519

 

 

139

 

 

380

 

 

0.01

 

Pension expenses (d)

 

-

 

 

-

-

 

 

235

 

 

235

 

 

71

 

 

164

 

 

-

 

Certain income tax items (f)

 

-

 

 

-

-

 

 

-

 

 

-

 

 

(1,052

)

 

1,052

 

 

0.02

 

Adjusted Non-GAAP

$

150,942

 

$

275,485

35.0

%

$

(1,014

)

$

267,637

 

$

39,819

 

$

227,818

 

$

3.65

 

 

 

 

 

 

 

 

 

Twelve Months Ended December 31, 2021

 

 

 

 

 

 

 

 

GAAP

$

639,276

 

$

821,707

29.5

%

$

17,203

 

$

806,193

 

$

113,350

 

$

692,843

 

$

11.17

 

Adjustments:

 

 

 

 

 

 

 

 

Purchased intangibles amortization (b)

 

(7,143

)

 

7,143

0.3

%

 

-

 

 

7,143

 

 

1,617

 

 

5,526

 

 

0.09

 

Restructuring costs and certain other items (c)

 

(7,338

)

 

7,338

0.3

%

 

(9,707

)

 

(2,369

)

 

(779

)

 

(1,590

)

 

(0.03

)

Pension expenses (d)

 

-

 

 

-

-

 

 

(294

)

 

(294

)

 

(74

)

 

(220

)

 

-

 

Litigation provision and settlement (e)

 

(5,165

)

 

5,165

0.2

%

 

(10,083

)

 

(4,918

)

 

(676

)

 

(4,242

)

 

(0.07

)

Certain income tax items (f)

 

-

 

 

-

-

 

 

-

 

 

-

 

 

(2,341

)

 

2,341

 

 

0.04

 

Adjusted Non-GAAP

$

619,630

 

$

841,353

30.2

%

$

(2,881

)

$

805,755

 

$

111,097

 

$

694,658

 

$

11.20

 

 

 

 

 

 

 

 

 

Twelve Months Ended December 31, 2020

 

 

 

 

 

 

 

 

GAAP

$

572,410

 

$

645,489

27.3

%

$

(1,775

)

$

610,914

 

$

89,343

 

$

521,571

 

$

8.36

 

Adjustments:

 

 

 

 

 

 

 

 

Purchased intangibles amortization (b)

 

(10,587

)

 

10,587

0.4

%

 

-

 

 

10,587

 

 

2,102

 

 

8,485

 

 

0.14

 

Asset Impairment (g)

 

(6,945

)

 

6,945

0.3

%

 

-

 

 

6,945

 

 

1,180

 

 

5,765

 

 

0.09

 

Restructuring costs and certain other items (c)

 

(35,196

)

 

35,196

1.5

%

 

(2,084

)

 

33,112

 

 

7,512

 

 

25,600

 

 

0.41

 

Pension expenses (d)

 

-

 

 

-

-

 

 

235

 

 

235

 

 

71

 

 

164

 

 

-

 

Litigation provision (e)

 

(1,180

)

 

1,180

-

 

 

-

 

 

1,180

 

 

283

 

 

897

 

 

0.01

 

Certain income tax items (f)

 

-

 

 

-

-

 

 

-

 

 

-

 

 

(2,619

)

 

2,619

 

 

0.04

 

Adjusted Non-GAAP

$

518,502

 

$

699,397

29.6

%

$

(3,624

)

$

662,973

 

$

97,872

 

$

565,101

 

$

9.05

 

____________________
(a) Selling & administrative expenses include purchased intangibles amortization, litigation provisions and settlements and asset impairments.
(b) The purchased intangibles amortization, a non-cash expense, was excluded to be consistent with how management evaluates the performance of its core business against historical operating results and the operating results of competitors over periods of time.
(c) Restructuring costs, mergers and acquisition costs and certain other items were excluded as the Company believes that the cost to consolidate operations, reduce overhead, acquire companies and certain other income or expense items are not normal and do not represent future ongoing business expenses of a specific function or geographic location of the Company.
(d) The pension settlement and curtailment expenses associated with certain defined benefit pension plans were excluded as the Company believes these expenses are not indicative of normal operating costs.
(e) Litigation settlement gains and provisions were excluded as these items are isolated, unpredictable and not expected to recur regularly.
(f) Certain income tax items were excluded as these non-cash expenses and benefits represent updates in management's assessment of ongoing examinations or other tax items that are not indicative of the Company’s normal or future income tax expense.
(g) The asset impairment, a non-cash expense, is a one-time charge related to the write-off of certain intangible assets and a contingent consideration liability that were both associated with a previous acquisition. The asset impairment was excluded as the Company does not believe these expenses are indicative of normal operating costs.

Contacts

Caspar Tudor, Director, Investor Relations – (508) 482-2429


Read full story here

Editor Details

  • Company:
    • Businesswire
Last Updated: 01-Feb-2022